media-coverage

30 AUG 2019 BIOTECH DAILY
2 SEP 2019 STOCKHEAD
TIM BOREHAM

Anatara’s greater prospects lie with human health, as a remedy for the common but difficult-to-treat afflictions of irritable bowel syndrome and inflammatory bowel disease(ulcerative colitis and Crohn’s disease).

He’s right: your columnist’s rigorous cross-checking of this claim reveals 530 million online references.

For the full article, please click here –
Dr Boreham’s Crucible – Anatara Lifesciences

Stuart Roberts of Pitt Street Research recently sat down with Steve Lydeamore, CEO of Anatara Lifesciences (ASX: ANR) to talk about the path to market for the company’s new dietary supplement product, called GaRP (gastrointestinal reprogramming).

Based on bromelain, GaRP has shown promise as a potential treatment for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Anatara believes there is significant upside for this product given the lack of strong treatment alternatives and the high prevalence of IBS and IBD.

Anatara Lifesciences CEO Steve Lydeamore sat down with Scott Power, Senior Research Analyst at Morgans Financial Limited yesterday to talk about the Company’s plans in human gastrointestinal health; developing a unique dietarysupplement to help IBS and IBD patients in the growing gut health market.

Anatara Lifesciences is pleased to release a copy of Anatara CEO, Steve Lydeamore, recent interview with Ky Chow of Proactive Investors Australia about the healthcare company’s renewed focus on human health, targeting the 11% of Australians affected by irritable bowel syndrome (IBS).

Lydeamore says the biotech firm’s dietary supplement is unlike other gut health products at the pharmacy because it seeks to repair lining of the gut.

Anatara Lifesciences is pleased to release a copy of Anatara CEO, Steve Lydeamore, recent interview with Tim McKinnon of ABN Newswire on the development of its Irritable Bowel Syndrome (IBS) dietary supplement to address the growing need for a product that addresses the full range of IBS symptoms.

8 FEB 2019 STOCKHEAD
Sam Jacobs

Australian biotech Anatara is busy working on its next big idea in the market for digestive health products.

The company says it’s concluded a successful proof of concept study for a dietary supplement that treats gastrointestinal problems.

For the full article, please click here.

21 JAN 2019 MERGERMARKET
Louise Weihart in Sydney

Anatara Lifesciences [ASX:ANR], an Australian developer of treatments for gastro-intestinal conditions with unmet medical need, is actively seeking deals to bolster its gastro-intestinal pipeline as it moves its focus to human health, said new Chief Executive Officer Steven Lydeamore.

For the full article, please click here –
190121 – Mergermarket – Anatara Lifesciences seeks deals to bolster human health

“Diarrhoea can be deadly in pig farming. Scour, as it’s called in the industry, kills tens of thousands of piglets every year. It’s traditionally been treated with antibiotics, but a Queensland scientist has developed a powerful, natural alternative from an extract found in pineapple stems”

The full story on Anatara and Detach™ was featured on Landline, today (19/03/17) and can be viewed online here.

Anatara Lifesciences is pleased to release a copy of Dr Mel Bridges, CEO & Chairman, recent interview with the Financial News Network (FNN) as part of the ASX The CEO Sessions in Sydney on 21st June 2016.

Please click here to view the FNN interview and corresponding ASX presentation.

CommSec’s Tom Piotrowski speaks with Anatara Lifesciences (ANR) Chief Scientific Officer, Dr Tracey Mynott about its non-antibiotic treatment for gastrointestinal diseases in production animals.

Click here to view the interview.

The Review on Antimicrobial Resistance (AMR) yesterday published its first paper, Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations.

Read More >>

Anatara Lifescience’s impending listing on the Australian Securities Exchange has been discussed in the Float Watch section of Australia’s only daily broadsheet newspaper The Australian.
Analyst Tim Morris, from wise-owl.com, notes that the global appetite for pork is strong as Anatara develops Detach™, our non-antibiotic treatment for diarrhoea in pigs.
He says Anatara controls intellectual property associated with an earlier formulation of Detach™ and that Anatara has further developed the therapy in preparation for field trials.
Read more here.

US President Barack Obama has issued an Executive Order that aims to combat the rise of antibiotic resistant bacteria that represent a serious threat to public health and the economy.

It says the US Federal Government will work domestically and internationally to “detect, prevent, and control illness and death related to antibiotic-resistant infections by implementing measures that reduce the emergence and spread of antibiotic-resistant bacteria and help ensure the continued availability of effective therapeutics for the treatment of bacterial infections”.

Measures to tackle antimicrobial resistance include eliminating “the use of medically important classes of antibiotics for growth promotion purposes in food-producing animals”.

The Executive Order can be found here.

A report to the President on combating antibiotic resistance by the President’s Council of Advisors on Science and Technology can be found here.

The Anatara team met senior business journalist Tim Boreham from The Australian newspaper recently to brief him on Anatara and our plans. He notes we’re raising $7 million from investors and that we’re intending to conduct new trials to get Detach re-registered in Australia. He suggests people read our prospectus when it’s lodged.

Read more »

Anatara’s chief scientific officer Dr Tracey Mynott was interviewed by ABC Radio Brisbane about how DetachTM was created and how treating diarrhoea in pigs could lead to treatments for humans.

To listen to the interview, click here.

The United Kingdom’s Royal Pharmaceutical Society has recommended better stewardship in the use of antibiotics be encouraged in the wake of growing international concerns about the rise of antimicrobial resistance.

The recommendation is one of seven the society makes in a report discussing challenges around developing new medicines, improving existing medicines and making better use of the ones already available.

“The increasing development of resistance to currently available antibiotics is a potentially serious threat to public health,” the report, titled New Medicines, Better Medicines, Better Use of Medicines, says.

It says the “profound consequences of antibiotic resistance for individual patients and for society create an ethical and moral imperative to protect public health by all reasonable means”.

Two leaders in human health have called for the
creation of a global organisation to tackle the growing threat of
antimicrobial resistance.

Mark Woolhouse, professor of infectious disease
epidemiology in the Centre for Immunity, Infection & Evolution at
the University of Edinburgh, and Jeremy Farrar, director of the global
health charity Wellcome Trust, have written in Nature seeking a
organisation similar to the Intergovernmental Panel on Climate Change.

“What is required is committed and coordinated action
on the root causes of resistance: the misuse of antimicrobials, the
paucity of development of new drugs and the lack of alternatives,”
they write.

“Guidelines must be implemented to improve the use of existing drugs;
the scientific and business worlds need incentives and a better
regulatory environment to develop new drugs and approaches, and those
working in both the animal and human sectors need education and
incentives to help them to change their ways.” Read more »

Bacterial resistance to antibiotics is now a major threat to public health, a new report by the World Health Organisation says. The WHO warns that without urgent action, common infections and minor injuries which have been treatable for decades could once again kill. Read more »

US regulators say 25 out of 26 drug makers that sell antibiotics used in livestock feed for growth enhancement have agreed to follow new guidelines that will make it illegal to use their products to create bigger animals. Read more »

The US Food and Drug Administration updates the animal pharmaceutical industry’s response to its plan to help phase out the use of medically important antimicrobials in food animals for food production purposes. Read more »

Lance Price is a public health researcher who works at the interface between science and policy to address the growing crisis of antibiotic resistance. To view his talk, delivered on March 11, 2014 in Manhattan, click here.

Policy-makers reacting the rise in bacteria resistant to antiobiotics.Read more »